vimarsana.com

Latest Breaking News On - Davidj wambeke - Page 1 : vimarsana.com

DiaMedica Therapeutics (DMAC) Set to Announce Earnings on Monday

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Monday, August 14th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings data on Monday, May 15th. The […]

Scott-kellen
Davidj-wambeke
Dimensional-fund-advisors
Citadel-advisors
Diamedica-therapeutics-inc
Renaissance-technologies
Securities-exchange-commission
Diamedica-therapeutics
Get-free-report
Medica-therapeutics
Exchange-commission
Street-group

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Insider Acquires $150,003.24 in Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Free Report) insider David J. Wambeke purchased 38,364 shares of the business’s stock in a transaction on Friday, June 23rd. The shares were bought at an average cost of $3.91 per share, for a total transaction of $150,003.24. Following the purchase, the insider now owns 507,114 shares of the company’s […]

Davidj-wambeke
Diamedica-therapeutics-inc
Nasdaq
Catalyst-financial-partners
Citadel-advisors
Renaissance-technologies
Diamedica-therapeutics
Free-report
Medica-therapeutics-trading-down
Medica-therapeutics
Street-corp

Insider Buying: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Insider Buys 38,364 Shares of Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) insider David J. Wambeke purchased 38,364 shares of the stock in a transaction on Friday, June 23rd. The stock was acquired at an average cost of $3.91 per share, with a total value of $150,003.24. Following the acquisition, the insider now owns 507,114 shares of the company’s stock, […]

Davidj-wambeke
Diamedica-therapeutics-company-profile
Renaissance-technologies
Securities-exchange-commission
Diamedica-therapeutics-inc
Nasdaq
Dimensional-fund-advisors
Citadel-advisors
Diamedica-therapeutics
Get-rating
Exchange-commission

DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Oppenheimer

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Thursday, The Fly reports. The brokerage currently has a $7.00 target price on the stock. Oppenheimer’s price target points to a potential upside of 64.71% from the company’s previous […]

Davidj-wambeke
Renaissance-technologies
Diamedica-therapeutics-inc
Diamedica-therapeutics-company-profile
Dimensional-fund-advisors
Securities-exchange-commission
Catalyst-financial-partners
Citadel-advisors
Diamedica-therapeutics
Get-rating
Medica-therapeutics

DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 10.1%

Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) were up 10.1% during mid-day trading on Monday . The company traded as high as $3.67 and last traded at $3.50. Approximately 190,500 shares were traded during trading, an increase of 269% from the average daily volume of 51,670 shares. The stock had previously closed at […]

Davidj-wambeke
Citadel-advisors
Catalyst-financial-partners
Renaissance-technologies
Dimensional-fund-advisors
Nasdaq
Diamedica-therapeutics-inc
Diamedica-therapeutics
Get-rating
Medica-therapeutics
Street-group

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.